Tag: 1

New York, United States, Aug. 15, 2025 (GLOBE NEWSWIRE) --  Graphjet Technology (NADSAQ: GTI) (the “Company”) today announced that its board of directors (the “Board”) has determined the effective date for the previously approved share consolidation of the Company’s ordinary shares at a ratio of 1-for-60  and to reduce the par value of the Company’s ordinary shares from $0.0001 per share to $0.006 per share (the “Share Consolidation”).

   
- Successfully initiated enrollment in advanced Phase 2 ovarian cancer trial

SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Shares of Nutex Health Inc. (NASDAQ: NUTX) experienced a precipitous decline today, falling as much as 24% in intraday trading. The significant drop followed the company’s disclosure that it would not timely submit its financial results for the quarter ended June 30, 2025 - a development related to an ongoing investigation by law firm Hagens Berman into possible securities violations.

SHANGHAI, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Smart Share Global Limited (Nasdaq: EM) (“Energy Monster” or the “Company”), a consumer tech company providing mobile device charging service, today announced that the board of directors received a preliminary non-binding proposal letter, dated August 13, 2025, from Hillhouse Investment Management, Ltd. (together with its affiliates, “Hillhouse”) to acquire all of the outstanding ordinary shares of the Company that are not already beneficially owned by Hillhouse or the Management Members (as defined below) for US$1.77 per ADS or US$0.885 per share in cash, subject to the acceptance by the Management Members of the similar rollover arrangement in the Merger Agreement (as defined below).

BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”), consisting of (i) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 4,250,718 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 2,833,812 shares of X4’s common stock granted to Mr. Kirske. In addition, effective on August 14, 2025, the company issued additional inducement awards to Dr. Craig, Mr. Volpone and Mr. Kirske under the 2019 Inducement Plan, consisting of (i) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Dr. Craig, (ii) options to purchase an aggregate of 529,201 shares of X4’s common stock granted to Mr. Volpone and (iii) options to purchase an aggregate of 352,800 shares of X4’s common stock granted to Mr. Kirske.

Hong Kong, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Mango Financial Limited (“Mango” or the "Company") today announced that it has initiated its digital currency strategy by introducing cryptocurrency elements into the Company’s financial operations.

SINGAPORE, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Ebang International Holdings Inc. (Nasdaq: EBON, the “Company,” “we,” “us” or “our”), today announced its unaudited financial results for the first six months of fiscal year 2025.

Transaction Expected to Close in the Coming Days

DALLAS, Aug. 15, 2025 (GLOBE NEWSWIRE) -- HF Sinclair Corporation (NYSE and NYSE Texas: DINO) (the “Corporation”) today announced the pricing terms for its previously announced cash tender offer (the “Tender Offer”) to purchase any and all of its outstanding notes listed in the table below (collectively, the “Notes” and each a “Series” of Notes). All other terms and conditions of the Tender Offer remain unchanged and are described in the Offer to Purchase, dated August 11, 2025 (the “Offer to Purchase”). Capitalized terms used in this news release and not defined herein have the meanings given to them in the Offer to Purchase.

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years